Temelimab (also known as GNbAC1) is an experimental monoclonal antibody drug for

immune system The immune system is a network of biological processes that protects an organism from diseases. It detects and responds to a wide variety of pathogens, from viruses to parasitic worms, as well as cancer cells and objects such as wood splinte ...

conditions that neutralizes the human

endogenous retrovirus Endogenous retroviruses (ERVs) are endogenous viral elements in the genome that closely resemble and can be derived from retroviruses. They are abundant in the genomes of jawed vertebrates, and they comprise up to 5–8% of the human genome (l ...

envelope protein

HERV-W Human Endogenous Retrovirus-W (HERV-W) is the coding for a protein that would normally be part of the envelope of one family of Human Endogenous Retro-Viruses, or HERVs. HERV-W encoding sequences makes up about 1% of the human genome and are pa ...

. It has been studied for

multiple sclerosis Multiple (cerebral) sclerosis (MS), also known as encephalomyelitis disseminata or disseminated sclerosis, is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This d ...

up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.

References

{{Medicine-stub Monoclonal antibodies Experimental monoclonal antibodies Long COVID Multiple sclerosis